Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2024

Open Access 01-12-2024 | Alzheimer's Disease | Review

Exercise mimetics: a novel strategy to combat neuroinflammation and Alzheimer’s disease

Author: Renqing Zhao

Published in: Journal of Neuroinflammation | Issue 1/2024

Login to get access

Abstract

Neuroinflammation is a pathological hallmark of Alzheimer’s disease (AD), characterized by the stimulation of resident immune cells of the brain and the penetration of peripheral immune cells. These inflammatory processes facilitate the deposition of amyloid-beta (Aβ) plaques and the abnormal hyperphosphorylation of tau protein. Managing neuroinflammation to restore immune homeostasis and decrease neuronal damage is a therapeutic approach for AD. One way to achieve this is through exercise, which can improve brain function and protect against neuroinflammation, oxidative stress, and synaptic dysfunction in AD models. The neuroprotective impact of exercise is regulated by various molecular factors that can be activated in the same way as exercise by the administration of their mimetics. Recent evidence has proven some exercise mimetics effective in alleviating neuroinflammation and AD, and, additionally, they are a helpful alternative option for patients who are unable to perform regular physical exercise to manage neurodegenerative disorders. This review focuses on the current state of knowledge on exercise mimetics, including their efficacy, regulatory mechanisms, progress, challenges, limitations, and future guidance for their application in AD therapy.
Literature
1.
Atella V, Piano Mortari A, Kopinska J, Belotti F, Lapi F, Cricelli C, Fontana L. Trends in age-related disease burden and healthcare utilization. Aging Cell. 2019;18: e12861.PubMedCrossRef
2.
Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15:565–81.PubMedCrossRef
3.
Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer’s disease. Lancet. 2021;397:1577–90.PubMedPubMedCentralCrossRef
4.
Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population estimate of people with clinical Alzheimer’s disease and mild cognitive impairment in the United States (2020–2060). Alzheimers Dement. 2021;17:1966–75.PubMedPubMedCentralCrossRef
5.
6.
McGee SL, Hargreaves M. Exercise adaptations: molecular mechanisms and potential targets for therapeutic benefit. Nat Rev Endocrinol. 2020;16:495–505.PubMedCrossRef
7.
Kelly RS, Kelly MP, Kelly P. Metabolomics, physical activity, exercise and health: a review of the current evidence. Biochim Biophys Acta Mol Basis Dis. 2020;186:165936.CrossRef
8.
Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007;30:464–72.PubMedCrossRef
9.
10.
Giorgetti E, Panesar M, Zhang Y, Joller S, Ronco M, Obrecht M, Lambert C, Accart N, Beckmann N, Doelemeyer A, et al. Modulation of microglia by voluntary exercise or CSF1R inhibition prevents age-related loss of functional motor units. Cell Rep. 2019;29(1539–1554): e1537.
11.
Li Z, Chen Q, Liu J, Du Y. Physical exercise ameliorates the cognitive function and attenuates the neuroinflammation of Alzheimer’s disease via miR-129–5p. Dement Geriatr Cogn Disord. 2020;49:163–9.PubMedCrossRef
12.
McDonnell MN, Smith AE, Mackintosh SF. Aerobic exercise to improve cognitive function in adults with neurological disorders: a systematic review. Arch Phys Med Rehabil. 2011;92:1044–52.PubMedCrossRef
13.
Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer’s disease. J Neurosci. 2005;25:4217–21.PubMedPubMedCentralCrossRef
14.
15.
Wang M, Zhang H, Liang J, Huang J, Chen N. Exercise suppresses neuroinflammation for alleviating Alzheimer’s disease. J Neuroinflammation. 2023;20:76.PubMedPubMedCentralCrossRef
16.
Lourenco MV, Frozza RL, de Freitas GB, Zhang H, Kincheski GC, Ribeiro FC, Goncalves RA, Clarke JR, Beckman D, Staniszewski A, et al. Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models. Nat Med. 2019;25:165–75.PubMedPubMedCentralCrossRef
17.
Reddy I, Yadav Y, Dey CS. Cellular and molecular regulation of exercise-a neuronal perspective. Cell Mol Neurobiol. 2023;43:1551–71.PubMedCrossRef
18.
Lu Y, Bu FQ, Wang F, Liu L, Zhang S, Wang G, Hu XY. Recent advances on the molecular mechanisms of exercise-induced improvements of cognitive dysfunction. Transl Neurodegener. 2023;12:9.PubMedPubMedCentralCrossRef
19.
Wrann CD, White JP, Salogiannnis J, Laznik-Bogoslavski D, Wu J, Ma D, Lin JD, Greenberg ME, Spiegelman BM. Exercise induces hippocampal BDNF through a PGC-1alpha/FNDC5 pathway. Cell Metab. 2013;18:649–59.PubMedPubMedCentralCrossRef
20.
21.
De Miguel Z, Khoury N, Betley MJ, Lehallier B, Willoughby D, Olsson N, Yang AC, Hahn O, Lu N, Vest RT, et al. Exercise plasma boosts memory and dampens brain inflammation via clusterin. Nature. 2021;600:494–9.ADSPubMedPubMedCentralCrossRef
22.
Horowitz AM, Fan X, Bieri G, Smith LK, Sanchez-Diaz CI, Schroer AB, Gontier G, Casaletto KB, Kramer JH, Williams KE, Villeda SA. Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain. Science. 2020;369:167–73.ADSPubMedPubMedCentralCrossRef
23.
Sleiman SF, Henry J, Al-Haddad R, El Hayek L, Abou Haidar E, Stringer T, Ulja D, Karuppagounder SS, Holson EB, Ratan RR, et al. Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body beta-hydroxybutyrate. Elife. 2016;5: e15092.PubMedPubMedCentralCrossRef
24.
Nigam SM, Xu S, Kritikou JS, Marosi K, Brodin L, Mattson MP. Exercise and BDNF reduce Abeta production by enhancing alpha-secretase processing of APP. J Neurochem. 2017;142:286–96.PubMedPubMedCentralCrossRef
25.
26.
27.
Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8:457–65.PubMedCrossRef
28.
Young MF, Valaris S, Wrann CD. A role for FNDC5/Irisin in the beneficial effects of exercise on the brain and in neurodegenerative diseases. Prog Cardiovasc Dis. 2019;62:172–8.PubMedPubMedCentralCrossRef
29.
30.
Beauchamp LC, Liu XM, Sedjahtera A, Bogeski M, Vella LJ, Bush AI, Adlard PA, Barnham KJ. S-adenosylmethionine rescues cognitive deficits in the rTg4510 animal model by stabilizing protein phosphatase 2A and reducing phosphorylated tau. J Alzheimers Dis. 2020;77:1705–15.PubMedCrossRef
31.
Wan X, Ma B, Wang X, Guo C, Sun J, Cui J, Li L. S-Adenosylmethionine alleviates amyloid-β-induced neural injury by enhancing trans-sulfuration pathway activity in astrocytes. J Alzheimers Dis. 2020;76:981–95.PubMedCrossRef
32.
33.
34.
Gubert C, Hannan AJ. Exercise mimetics: harnessing the therapeutic effects of physical activity. Nat Rev Drug Discov. 2021;20:862–79.PubMedCrossRef
35.
Ozben T, Ozben S. Neuro-inflammation and anti-inflammatory treatment options for Alzheimer’s disease. Clin Biochem. 2019;72:87–9.PubMedCrossRef
36.
37.
38.
Panza F, Lozupone M, Seripa D, Imbimbo BP. Amyloid-beta immunotherapy for Alzheimer disease: is it now a long shot? Ann Neurol. 2019;85:303–15.PubMedCrossRef
39.
Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M, Wolfson L. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer’s disease. Neurology. 1988;38:1682–7.PubMedCrossRef
40.
Jellinger K. Prevalence of Alzheimer’s disease in very elderly people: a prospective neuropathological study. Neurology. 2002;58:671–2 (author reply 671-672).PubMedCrossRef
41.
Steubler V, Erdinger S, Back MK, Ludewig S, Fassler D, Richter M, Han K, Slomianka L, Amrein I, von Engelhardt J, et al. Loss of all three APP family members during development impairs synaptic function and plasticity, disrupts learning, and causes an autism-like phenotype. EMBO J. 2021;40: e107471.PubMedPubMedCentralCrossRef
42.
Sturchio A, Dwivedi AK, Young CB, Malm T, Marsili L, Sharma JS, Mahajan A, Hill EJ, Andaloussi SE, Poston KL, et al. High cerebrospinal amyloid-beta 42 is associated with normal cognition in individuals with brain amyloidosis. EClinicalMedicine. 2021;38: 100988.PubMedPubMedCentralCrossRef
43.
Maccioni RB, Tapia JP, Guzman-Martinez L. Pathway to tau modifications and the origins of Alzheimer’s disease. Arch Med Res. 2018;49:130–1.PubMedCrossRef
44.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.PubMedCrossRef
45.
Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer’s disease. Arch Med Res. 2008;39:1–16.PubMedCrossRef
46.
Heneka MT, McManus RM, Latz E. Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci. 2018;19:610–21.PubMedCrossRef
47.
Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17:157–72.PubMedCrossRef
48.
Li X, Shi X, McPherson M, Hager M, Garcia GG, Miller RA. Cap-independent translation of GPLD1 enhances markers of brain health in long-lived mutant and drug-treated mice. Aging Cell. 2022;21: e13685.PubMedPubMedCentralCrossRef
49.
Huang Y, Happonen KE, Burrola PG, O’Connor C, Hah N, Huang L, Nimmerjahn A, Lemke G. Microglia use TAM receptors to detect and engulf amyloid beta plaques. Nat Immunol. 2021;22:586–94.PubMedPubMedCentralCrossRef
50.
Maccioni RB, Rojo LE, Fernandez JA, Kuljis RO. The role of neuroimmunomodulation in Alzheimer’s disease. Ann NY Acad Sci. 2009;1153:240–6.ADSPubMedCrossRef
51.
52.
Lyman M, Lloyd DG, Ji X, Vizcaychipi MP, Ma D. Neuroinflammation: the role and consequences. Neurosci Res. 2014;79:1–12.PubMedCrossRef
53.
Gutierrez EG, Banks WA, Kastin AJ. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J Neuroimmunol. 1993;47:169–76.PubMedCrossRef
54.
Terrando N, Eriksson LI, Ryu JK, Yang T, Monaco C, Feldmann M, Jonsson Fagerlund M, Charo IF, Akassoglou K, Maze M. Resolving postoperative neuroinflammation and cognitive decline. Ann Neurol. 2011;70:986–95.PubMedPubMedCentralCrossRef
55.
Wong D, Dorovini-Zis K, Vincent SR. Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier. Exp Neurol. 2004;190:446–55.PubMedCrossRef
56.
Morales I, Guzman-Martinez L, Cerda-Troncoso C, Farias GA, Maccioni RB. Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci. 2014;8:112.PubMedPubMedCentralCrossRef
57.
Lee HJ, Kim C, Lee SJ. Alpha-synuclein stimulation of astrocytes: potential role for neuroinflammation and neuroprotection. Oxid Med Cell Longev. 2010;3:283–7.PubMedPubMedCentralCrossRef
58.
Mann CN, Devi SS, Kersting CT, Bleem AV, Karch CM, Holtzman DM, Gallardo G. Astrocytic alpha2-Na(+)/K(+) ATPase inhibition suppresses astrocyte reactivity and reduces neurodegeneration in a tauopathy mouse model. Sci Transl Med. 2022;14:eabm4107.PubMedPubMedCentralCrossRef
59.
60.
McAlpine CS, Park J, Griciuc A, Kim E, Choi SH, Iwamoto Y, Kiss MG, Christie KA, Vinegoni C, Poller WC, et al. Astrocytic interleukin-3 programs microglia and limits Alzheimer’s disease. Nature. 2021;595:701–6.ADSPubMedPubMedCentralCrossRef
61.
Ahmad MA, Kareem O, Khushtar M, Akbar M, Haque MR, Iqubal A, Haider MF, Pottoo FH, Abdulla FS, Al-Haidar MB, Alhajri N. Neuroinflammation: a potential risk for dementia. Int J Mol Sci. 2022;23:616.PubMedPubMedCentralCrossRef
62.
Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease–a double-edged sword. Neuron. 2002;35:419–32.PubMedCrossRef
63.
64.
Anderson WD, Vadigepalli R. Neuroinflammation, glia, and cytokines: networks of networks. In: Jaeger D, Jung R, editors. Encyclopedia of computational neuroscience. New York: Springer; 2022. p. 2281–7.CrossRef
65.
Kempuraj D, Thangavel R, Natteru PA, Selvakumar GP, Saeed D, Zahoor H, Zaheer S, Iyer SS, Zaheer A. Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine. 2016;1:1003.PubMedPubMedCentral
66.
Mishra A, Kim HJ, Shin AH, Thayer SA. Synapse loss induced by interleukin-1β requires pre- and post-synaptic mechanisms. J Neuroimmune Pharmacol. 2012;7:571–8.PubMedPubMedCentralCrossRef
67.
Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388–405.PubMedPubMedCentralCrossRef
68.
69.
Wen H, Miao EA, Ting JP. Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity. 2013;39:432–41.PubMedCrossRef
70.
Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13:397–411.PubMedCrossRef
71.
Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-like proteins in immunity, inflammation and disease. Nat Immunol. 2006;7:1250–7.PubMedCrossRef
72.
Platnich JM, Muruve DA. NOD-like receptors and inflammasomes: a review of their canonical and non-canonical signaling pathways. Arch Biochem Biophys. 2019;670:4–14.PubMedCrossRef
73.
74.
Sekiya M, Wang M, Fujisaki N, Sakakibara Y, Quan X, Ehrlich ME, De Jager PL, Bennett DA, Schadt EE, Gandy S, et al. Integrated biology approach reveals molecular and pathological interactions among Alzheimer’s Aβ42, Tau, TREM2, and TYROBP in Drosophila models. Genome Med. 2018;10:1.CrossRef
75.
Baufeld C, O’Loughlin E, Calcagno N, Madore C, Butovsky O. Differential contribution of microglia and monocytes in neurodegenerative diseases. J Neural Transm (Vienna). 2018;125:809–26.PubMedCrossRef
76.
Dos Santos SE, Medeiros M, Porfirio J, Tavares W, Pessoa L, Grinberg L, Leite REP, Ferretti-Rebustini REL, Suemoto CK, Filho WJ, et al. Similar microglial cell densities across brain structures and mammalian species: implications for brain tissue function. J Neurosci. 2020;40:4622–43.PubMedPubMedCentralCrossRef
77.
Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314–8.ADSPubMedCrossRef
78.
Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8:752–8.PubMedCrossRef
79.
Stence N, Waite M, Dailey ME. Dynamics of microglial activation: a confocal time-lapse analysis in hippocampal slices. Glia. 2001;33:256–66.PubMedCrossRef
80.
81.
Davies DS, Ma J, Jegathees T, Goldsbury C. Microglia show altered morphology and reduced arborization in human brain during aging and Alzheimer’s disease. Brain Pathol. 2017;27:795–808.PubMedCrossRef
82.
Rawji KS, Mishra MK, Michaels NJ, Rivest S, Stys PK, Yong VW. Immunosenescence of microglia and macrophages: impact on the ageing central nervous system. Brain. 2016;139:653–61.PubMedPubMedCentralCrossRef
83.
Bisht K, Sharma KP, Lecours C, Sanchez MG, El Hajj H, Milior G, Olmos-Alonso A, Gomez-Nicola D, Luheshi G, Vallieres L, et al. Dark microglia: a new phenotype predominantly associated with pathological states. Glia. 2016;64:826–39.PubMedPubMedCentralCrossRef
84.
Niraula A, Sheridan JF, Godbout JP. Microglia priming with aging and stress. Neuropsychopharmacology. 2017;42:318–33.PubMedCrossRef
85.
Plescher M, Seifert G, Hansen JN, Bedner P, Steinhauser C, Halle A. Plaque-dependent morphological and electrophysiological heterogeneity of microglia in an Alzheimer’s disease mouse model. Glia. 2018;66:1464–80.PubMedCrossRef
86.
Sanchez-Mejias E, Navarro V, Jimenez S, Sanchez-Mico M, Sanchez-Varo R, Nunez-Diaz C, Trujillo-Estrada L, Davila JC, Vizuete M, Gutierrez A, Vitorica J. Soluble phospho-tau from Alzheimer’s disease hippocampus drives microglial degeneration. Acta Neuropathol. 2016;132:897–916.PubMedPubMedCentralCrossRef
87.
Doorn KJ, Goudriaan A, Blits-Huizinga C, Bol JG, Rozemuller AJ, Hoogland PV, Lucassen PJ, Drukarch B, van de Berg WD, van Dam AM. Increased amoeboid microglial density in the olfactory bulb of Parkinson’s and Alzheimer’s patients. Brain Pathol. 2014;24:152–65.PubMedCrossRef
88.
Navarro V, Sanchez-Mejias E, Jimenez S, Munoz-Castro C, Sanchez-Varo R, Davila JC, Vizuete M, Gutierrez A, Vitorica J. Microglia in Alzheimer’s disease: activated, dysfunctional or degenerative. Front Aging Neurosci. 2018;10:140.PubMedPubMedCentralCrossRef
89.
Varnum MM, Ikezu T. The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer’s disease brain. Arch Immunol Ther Exp (Warsz). 2012;60:251–66.PubMedCrossRef
90.
91.
Colonna M, Brioschi S. Neuroinflammation and neurodegeneration in human brain at single-cell resolution. Nat Rev Immunol. 2019;20:81–2.CrossRef
92.
Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell. 2017;169(1276–1290): e1217.
93.
94.
Galatro TF, Holtman IR, Lerario AM, Vainchtein ID, Brouwer N, Sola PR, Veras MM, Pereira TF, Leite REP, Moller T, et al. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nat Neurosci. 2017;20:1162–71.PubMedCrossRef
95.
Mathys H, Adaikkan C, Gao F, Young JZ, Manet E, Hemberg M, De Jager PL, Ransohoff RM, Regev A, Tsai LH. Temporal tracking of microglia activation in neurodegeneration at single-cell resolution. Cell Rep. 2017;21:366–80.PubMedPubMedCentralCrossRef
96.
Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PCG, Ngu H, et al. Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer’s disease not evident in mouse models. Cell Rep. 2018;22:832–47.PubMedCrossRef
97.
Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929–47.PubMedPubMedCentralCrossRef
98.
McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett. 1987;79:195–200.PubMedCrossRef
99.
Tooyama I, Kimura H, Akiyama H, McGeer PL. Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimer’s disease. Brain Res. 1990;523:273–80.PubMedCrossRef
100.
Hayes A, Thaker U, Iwatsubo T, Pickering-Brown SM, Mann DM. Pathological relationships between microglial cell activity and tau and amyloid beta protein in patients with Alzheimer’s disease. Neurosci Lett. 2002;331:171–4.PubMedCrossRef
101.
Dani M, Wood M, Mizoguchi R, Fan Z, Walker Z, Morgan R, Hinz R, Biju M, Kuruvilla T, Brooks DJ, Edison P. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer’s disease. Brain. 2018;141:2740–54.PubMed
102.
Del Bo R, Angeretti N, Lucca E, De Simoni MG, Forloni G. Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and beta-amyloid production in cultures. Neurosci Lett. 1995;188:70–4.PubMedCrossRef
103.
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000;21:383–421.PubMedPubMedCentralCrossRef
104.
105.
Yang T, Li S, Xu H, Walsh DM, Selkoe DJ. Large soluble oligomers of amyloid beta-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. J Neurosci. 2017;37:152–63.PubMedPubMedCentralCrossRef
106.
Zhong L, Wang Z, Wang D, Wang Z, Martens YA, Wu L, Xu Y, Wang K, Li J, Huang R, et al. Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2). Mol Neurodegener. 2018;13:1.CrossRef
107.
Doens D, Fernández PL. Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis. J Neuroinflammation. 2014;11:48.PubMedPubMedCentralCrossRef
108.
Venegas C, Heneka MT. Danger-associated molecular patterns in Alzheimer’s disease. J Leukoc Biol. 2017;101:87–98.PubMedCrossRef
109.
Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B, Rube CE, Walter J, Heneka MT, Hartmann T, et al. TLR2 is a primary receptor for Alzheimer’s amyloid beta peptide to trigger neuroinflammatory activation. J Immunol. 2012;188:1098–107.PubMedCrossRef
110.
Murgas P, Godoy B, von Bernhardi R. Abeta potentiates inflammatory activation of glial cells induced by scavenger receptor ligands and inflammatory mediators in culture. Neurotox Res. 2012;22:69–78.PubMedCrossRef
111.
Alawieyah Syed Mortadza S, Sim JA, Neubrand VE, Jiang LH. A critical role of TRPM2 channel in Abeta(42) -induced microglial activation and generation of tumor necrosis factor-alpha. Glia. 2018;66:562–75.PubMedCrossRef
112.
Husemann J, Loike JD, Kodama T, Silverstein SC. Scavenger receptor class B type I (SR-BI) mediates adhesion of neonatal murine microglia to fibrillar beta-amyloid. J Neuroimmunol. 2001;114:142–50.PubMedCrossRef
113.
114.
115.
Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674–8.ADSPubMedCrossRef
116.
117.
Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368:107–16.PubMedCrossRef
118.
Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J Exp Med. 2015;212:287–95.PubMedPubMedCentralCrossRef
119.
Jay TR, von Saucken VE, Landreth GE. TREM2 in Neurodegenerative diseases. Mol Neurodegener. 2017;12:1.CrossRef
120.
Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell. 2017;170(649–663): e613.
121.
Paresce DM, Chung H, Maxfield FR. Slow degradation of aggregates of the Alzheimer’s disease amyloid beta-protein by microglial cells. J Biol Chem. 1997;272:29390–7.PubMedCrossRef
122.
Streit WJ, Braak H, Xue Q-S, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease. Acta Neuropathol. 2009;118:475–85.PubMedPubMedCentralCrossRef
123.
Raha-Chowdhury R, Henderson JW, Raha AA, Stott SRW, Vuono R, Foscarin S, Wilson L, Annus T, Fincham R, Allinson K, et al. Erythromyeloid-derived TREM2: a major determinant of Alzheimer’s disease pathology in Down Syndrome. J Alzheimers Dis. 2018;61:1143–62.PubMedPubMedCentralCrossRef
124.
Streit WJ. Microglial senescence: does the brain’s immune system have an expiration date? Trends Neurosci. 2006;29:506–10.PubMedCrossRef
125.
Streit WJ, Sammons NW, Kuhns AJ, Sparks DL. Dystrophic microglia in the aging human brain. Glia. 2004;45:208–12.PubMedCrossRef
126.
Hawcroft G, Gardner SH, Hull MA. Activation of peroxisome proliferator-activated receptor γ does not explain the antiproliferative activity of the nonsteroidal anti-inflammatory drug indomethacin on human colorectal cancer cells. J Pharmacol Exp Ther. 2003;305:632–7.PubMedCrossRef
127.
Chen C-H, Zhou W, Liu S, Deng Y, Cai F, Tone M, Tone Y, Tong Y, Song W. Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. Int J Neuropsychopharmacol. 2011;15:77–90.PubMedCrossRef
128.
Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213:667–75.PubMedPubMedCentralCrossRef
129.
Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, Vieira-Saecker A, Schwartz S, Santarelli F, Kummer MP, et al. Microglia-derived ASC specks cross-seed amyloid-beta in Alzheimer’s disease. Nature. 2017;552:355–61.ADSPubMedCrossRef
130.
Morales I, Jimenez JM, Mancilla M, Maccioni RB. Tau oligomers and fibrils induce activation of microglial cells. J Alzheimers Dis. 2013;37:849–56.PubMedCrossRef
131.
Wes PD, Easton A, Corradi J, Barten DM, Devidze N, DeCarr LB, Truong A, He A, Barrezueta NX, Polson C, et al. Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer’s disease. PLoS ONE. 2014;9: e106050.ADSPubMedPubMedCentralCrossRef
132.
Bolos M, Llorens-Martin M, Jurado-Arjona J, Hernandez F, Rabano A, Avila J. Direct evidence of internalization of tau by microglia in vitro and in vivo. J Alzheimers Dis. 2016;50:77–87.PubMedCrossRef
133.
Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, Wolozin B, Butovsky O, Kugler S, Ikezu T. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18:1584–93.PubMedPubMedCentralCrossRef
134.
Felsky D, Roostaei T, Nho K, Risacher SL, Bradshaw EM, Petyuk V, Schneider JA, Saykin A, Bennett DA, De Jager PL. Neuropathological correlates and genetic architecture of microglial activation in elderly human brain. Nat Commun. 2019;10:409.ADSPubMedPubMedCentralCrossRef
135.
Chen W, Abud EA, Yeung ST, Lakatos A, Nassi T, Wang J, Blum D, Buee L, Poon WW, Blurton-Jones M. Increased tauopathy drives microglia-mediated clearance of beta-amyloid. Acta Neuropathol Commun. 2016;4:63.PubMedPubMedCentralCrossRef
136.
Pekny M, Wilhelmsson U, Pekna M. The dual role of astrocyte activation and reactive gliosis. Neurosci Lett. 2014;565:30–8.PubMedCrossRef
137.
Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46:957–67.PubMedCrossRef
138.
Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–7.ADSPubMedPubMedCentralCrossRef
139.
140.
141.
Thal DR, Schultz C, Dehghani F, Yamaguchi H, Braak H, Braak E. Amyloid beta-protein (Abeta)-containing astrocytes are located preferentially near N-terminal-truncated Abeta deposits in the human entorhinal cortex. Acta Neuropathol. 2000;100:608–17.PubMedCrossRef
142.
Funato H, Yoshimura M, Yamazaki T, Saido TC, Ito Y, Yokofujita J, Okeda R, Ihara Y. Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. Am J Pathol. 1998;152:983–92.PubMedPubMedCentral
143.
Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, Bae JY, Kim T, Lee J, Chun H, et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease. Nat Med. 2014;20:886–96.PubMedPubMedCentralCrossRef
144.
Chang J, Liu F, Lee M, Wu B, Ting K, Zara JN, Soo C, Al Hezaimi K, Zou W, Chen X, et al. NF-kappaB inhibits osteogenic differentiation of mesenchymal stem cells by promoting beta-catenin degradation. Proc Natl Acad Sci USA. 2013;110:9469–74.ADSPubMedPubMedCentralCrossRef
145.
Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18:419–34.PubMedPubMedCentralCrossRef
146.
Bettcher BM, Tansey MG, Dorothee G, Heneka MT. Peripheral and central immune system crosstalk in Alzheimer disease—a research prospectus. Nat Rev Neurol. 2021;17:689–701.PubMedPubMedCentralCrossRef
147.
Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, Van Leuven F. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation. 2005;2:22.PubMedPubMedCentralCrossRef
148.
Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Brayne C, Burns A, Cohen-Mansfield J, Cooper C, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413–46.PubMedPubMedCentralCrossRef
149.
Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13:788–94.PubMedCrossRef
150.
Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol Med. 2009;39:3–11.PubMedCrossRef
151.
Buchman AS, Boyle PA, Yu L, Shah RC, Wilson RS, Bennett DA. Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology. 2012;78:1323–9.PubMedPubMedCentralCrossRef
152.
Silva MVF, Loures CMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MDG. Alzheimer’s disease: risk factors and potentially protective measures. J Biomed Sci. 2019;26:33.PubMedPubMedCentralCrossRef
153.
Brown BM, Peiffer JJ, Martins RN. Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer’s disease? Mol Psychiatry. 2013;18:864–74.PubMedCrossRef
154.
Vital TM, Hernandez SSS, Pedroso RV, Teixeira CVL, Garuffi M, Stein AM, Costa JLR, Stella F. Effects of weight training on cognitive functions in elderly with Alzheimer’s disease. Dement Neuropsychol. 2012;6:253–9.PubMedPubMedCentralCrossRef
155.
Toots A, Littbrand H, Bostrom G, Hornsten C, Holmberg H, Lundin-Olsson L, Lindelof N, Nordstrom P, Gustafson Y, Rosendahl E. Effects of exercise on cognitive function in older people with dementia: a randomized controlled trial. J Alzheimers Dis. 2017;60:323–32.PubMedPubMedCentralCrossRef
156.
Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, Plymate SR, Fishel MA, Watson GS, Cholerton BA, et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol. 2010;67:71–9.PubMedPubMedCentralCrossRef
157.
Weuve J, Kang JH, Manson JE, Breteler MM, Ware JH, Grodstein F. Physical activity, including walking, and cognitive function in older women. JAMA. 2004;292:1454–61.PubMedCrossRef
158.
Scherder EJ, Van Paasschen J, Deijen JB, Van Der Knokke S, Orlebeke JF, Burgers I, Devriese PP, Swaab DF, Sergeant JA. Physical activity and executive functions in the elderly with mild cognitive impairment. Aging Ment Health. 2005;9:272–80.PubMedCrossRef
159.
Yu Q, Li X, Wang J, Li Y. Effect of exercise training on long-term potentiation and NMDA receptor channels in rats with cerebral infarction. Exp Ther Med. 2013;6:1431–6.PubMedPubMedCentralCrossRef
160.
Liu HL, Zhao G, Zhang H, Shi LD. Long-term treadmill exercise inhibits the progression of Alzheimer’s disease-like neuropathology in the hippocampus of APP/PS1 transgenic mice. Behav Brain Res. 2013;256:261–72.PubMedCrossRef
161.
Kang EB, Kwon IS, Koo JH, Kim EJ, Kim CH, Lee J, Yang CH, Lee YI, Cho IH, Cho JY. Treadmill exercise represses neuronal cell death and inflammation during Abeta-induced ER stress by regulating unfolded protein response in aged presenilin 2 mutant mice. Apoptosis. 2013;18:1332–47.PubMedCrossRef
162.
El Hayek L, Khalifeh M, Zibara V, Abi Assaad R, Emmanuel N, Karnib N, El-Ghandour R, Nasrallah P, Bilen M, Ibrahim P, et al. Lactate mediates the effects of exercise on learning and memory through SIRT1-dependent activation of hippocampal brain-derived neurotrophic factor (BDNF). J Neurosci. 2019;39:2369–82.PubMedPubMedCentral
163.
Baranowski BJ, Hayward GC, Marko DM, MacPherson REK. Examination of BDNF treatment on BACE1 activity and acute exercise on brain BDNF signaling. Front Cell Neurosci. 2021;15: 665867.PubMedPubMedCentralCrossRef
164.
Scheffer DDL, Latini A. Exercise-induced immune system response: anti-inflammatory status on peripheral and central organs. Biochim Biophys Acta Mol Basis Dis. 2020;1866: 165823.PubMedPubMedCentralCrossRef
165.
Wang J, Liu S, Li G, Xiao J. Exercise regulates the immune system. Adv Exp Med Biol. 2020;1228:395–408.PubMedCrossRef
166.
Mahalakshmi B, Maurya N, Lee SD, Bharath Kumar V. Possible neuroprotective mechanisms of physical exercise in neurodegeneration. Int J Mol Sci. 2020;21:5895.PubMedPubMedCentralCrossRef
167.
168.
Simpson RJ, Campbell JP, Gleeson M, Kruger K, Nieman DC, Pyne DB, Turner JE, Walsh NP. Can exercise affect immune function to increase susceptibility to infection? Exerc Immunol Rev. 2020;26:8–22.PubMed
169.
Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol. 2011;11:607–15.PubMedCrossRef
170.
Scheffer DDL, Ghisoni K, Aguiar AS Jr, Latini A. Moderate running exercise prevents excessive immune system activation. Physiol Behav. 2019;204:248–55.PubMedCrossRef
171.
Nieman DC, Wentz LM. The compelling link between physical activity and the body’s defense system. J Sport Health Sci. 2019;8:201–17.PubMedCrossRef
172.
Metsios GS, Moe RH, Kitas GD. Exercise and inflammation. Best Pract Res Clin Rheumatol. 2020;34: 101504.PubMedCrossRef
173.
Hamer M, Sabia S, Batty GD, Shipley MJ, Tabak AG, Singh-Manoux A, Kivimaki M. Physical activity and inflammatory markers over 10 years: follow-up in men and women from the Whitehall II cohort study. Circulation. 2012;126:928–33.PubMedPubMedCentralCrossRef
174.
Pitsavos C, Panagiotakos DB, Chrysohoou C, Kavouras S, Stefanadis C. The associations between physical activity, inflammation, and coagulation markers, in people with metabolic syndrome: the ATTICA study. Eur J Cardiovasc Prev Rehabil. 2005;12:151–8.PubMedCrossRef
175.
Kadoglou NP, Perrea D, Iliadis F, Angelopoulou N, Liapis C, Alevizos M. Exercise reduces resistin and inflammatory cytokines in patients with type 2 diabetes. Diabetes Care. 2007;30:719–21.PubMedCrossRef
176.
Timmerman KL, Flynn MG, Coen PM, Markofski MM, Pence BD. Exercise training-induced lowering of inflammatory (CD14+CD16+) monocytes: a role in the anti-inflammatory influence of exercise? J Leukoc Biol. 2008;84:1271–8.PubMedCrossRef
177.
Oliveira M, Gleeson M. The influence of prolonged cycling on monocyte Toll-like receptor 2 and 4 expression in healthy men. Eur J Appl Physiol. 2010;109:251–7.PubMedCrossRef
178.
Lancaster GI, Khan Q, Drysdale P, Wallace F, Jeukendrup AE, Drayson MT, Gleeson M. The physiological regulation of toll-like receptor expression and function in humans. J Physiol. 2005;563:945–55.PubMedPubMedCentralCrossRef
179.
Lavin KM, Perkins RK, Jemiolo B, Raue U, Trappe SW, Trappe TA. Effects of aging and lifelong aerobic exercise on basal and exercise-induced inflammation. J Appl Physiol. 1985;2020(128):87–99.
180.
Nilsson MI, Bourgeois JM, Nederveen JP, Leite MR, Hettinga BP, Bujak AL, May L, Lin E, Crozier M, Rusiecki DR, et al. Lifelong aerobic exercise protects against inflammaging and cancer. PLoS ONE. 2019;14: e0210863.PubMedPubMedCentralCrossRef
181.
Valenzuela PL, Castillo-Garcia A, Morales JS, de la Villa P, Hampel H, Emanuele E, Lista S, Lucia A. Exercise benefits on Alzheimer’s disease: State-of-the-science. Ageing Res Rev. 2020;62: 101108.PubMedCrossRef
182.
Ingold M, Tulliani N, Chan CCH, Liu KPY. Cognitive function of older adults engaging in physical activity. BMC Geriatr. 2020;20:1.CrossRef
183.
Gheysen F, Poppe L, DeSmet A, Swinnen S, Cardon G, De Bourdeaudhuij I, Chastin S, Fias W. Physical activity to improve cognition in older adults: can physical activity programs enriched with cognitive challenges enhance the effects? A systematic review and meta-analysis. Int J Behav Nutr Phys Act. 2018;15:63.PubMedPubMedCentralCrossRef
184.
Sellami M, Gasmi M, Denham J, Hayes LD, Stratton D, Padulo J, Bragazzi N. Effects of acute and chronic exercise on immunological parameters in the elderly aged: can physical activity counteract the effects of aging? Front Immunol. 2018;9:2187.PubMedPubMedCentralCrossRef
185.
Zhang SS, Zhu L, Peng Y, Zhang L, Chao FL, Jiang L, Xiao Q, Liang X, Tang J, Yang H, et al. Long-term running exercise improves cognitive function and promotes microglial glucose metabolism and morphological plasticity in the hippocampus of APP/PS1 mice. J Neuroinflammation. 2022;19:34.PubMedPubMedCentralCrossRef
186.
Jensen CS, Bahl JM, Østergaard LB, Høgh P, Wermuth L, Heslegrave A, Zetterberg H, Heegaard NHH, Hasselbalch SG, Simonsen AH. Exercise as a potential modulator of inflammation in patients with Alzheimer’s disease measured in cerebrospinal fluid and plasma. Exp Gerontol. 2019;121:91–8.PubMedCrossRef
187.
Ercan Z, Bilek F, Demir CF. The effect of aerobic exercise on neurofilament light chain and glial fibrillary acidic protein level in patients with relapsing remitting type multiple sclerosis. Mult Scler Relat Disord. 2021;55: 103219.PubMedCrossRef
188.
Mela V, Mota BC, Milner M, McGinley A, Mills KHG, Kelly AM, Lynch MA. Exercise-induced re-programming of age-related metabolic changes in microglia is accompanied by a reduction in senescent cells. Brain Behav Immun. 2020;87:413–28.PubMedCrossRef
189.
Ke HC, Huang HJ, Liang KC, Hsieh-Li HM. Selective improvement of cognitive function in adult and aged APP/PS1 transgenic mice by continuous non-shock treadmill exercise. Brain Res. 2011;1403:1–11.PubMedCrossRef
190.
Zhang X, He Q, Huang T, Zhao N, Liang F, Xu B, Chen X, Li T, Bi J. Treadmill exercise decreases abeta deposition and counteracts cognitive decline in APP/PS1 mice, possibly via hippocampal microglia modifications. Front Aging Neurosci. 2019;11:78.PubMedPubMedCentralCrossRef
191.
Choi DH, Kwon IS, Koo JH, Jang YC, Kang EB, Byun JE, Um HS, Park HS, Yeom DC, Cho IH, Cho JY. The effect of treadmill exercise on inflammatory responses in rat model of streptozotocin-induced experimental dementia of Alzheimer’s type. J Exerc Nutrition Biochem. 2014;18:225–33.PubMedPubMedCentralCrossRef
192.
Koo J-H, Jang Y-C, Hwang D-J, Um H-S, Lee N-H, Jung J-H, Cho J-Y. Treadmill exercise produces neuroprotective effects in a murine model of Parkinson’s disease by regulating the TLR2/MyD88/NF-κB signaling pathway. Neuroscience. 2017;356:102–13.PubMedCrossRef
193.
Rosa JM, Camargo A, Wolin IAV, Kaster MP, Rodrigues ALS. Physical exercise prevents amyloid beta (1–40)-induced disturbances in NLRP3 inflammasome pathway in the hippocampus of mice. Metab Brain Dis. 2021;36:351–9.PubMedCrossRef
194.
Lonnemann N, Hosseini S, Marchetti C, Skouras DB, Stefanoni D, D’Alessandro A, Dinarello CA, Korte M. The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA. 2020;117:32145–54.ADSPubMedPubMedCentralCrossRef
195.
196.
Sun L-n, Qi Js, Gao R. Physical exercise reserved amyloid-beta induced brain dysfunctions by regulating hippocampal neurogenesis and inflammatory response via MAPK signaling. Brain Res. 2018;1697:1–9.PubMedCrossRef
197.
198.
Babcock KR, Page JS, Fallon JR, Webb AE. Adult hippocampal neurogenesis in aging and Alzheimer’s disease. Stem Cell Rep. 2021;16:681–93.CrossRef
199.
Sung PS, Lin PY, Liu CH, Su HC, Tsai KJ. Neuroinflammation and neurogenesis in Alzheimer’s disease and potential therapeutic approaches. Int J Mol Sci. 2020;21:701.PubMedPubMedCentralCrossRef
200.
Gerberding AL, Zampar S, Stazi M, Liebetanz D, Wirths O. Physical activity ameliorates impaired hippocampal neurogenesis in the Tg4-42 mouse model of Alzheimer’s disease. ASN Neuro. 2019;11:1759091419892692.PubMedPubMedCentralCrossRef
201.
Abshenas R, Artimani T, Shahidi S, Ranjbar A, Komaki A, Salehi I, Amiri I, Soleimani Asl S. Treadmill exercise enhances the promoting effects of preconditioned stem cells on memory and neurogenesis in Abeta-induced neurotoxicity in the rats. Life Sci. 2020;249: 117482.PubMedCrossRef
202.
203.
Yamazaki Y, Kanekiyo T. Blood-brain barrier dysfunction and the pathogenesis of Alzheimer’s disease. Int J Mol Sci. 1965;18:1965.CrossRef
204.
Wang D, Chen F, Han Z, Yin Z, Ge X, Lei P. Relationship between amyloid-β deposition and blood-brain barrier dysfunction in Alzheimer’s disease. Front Cell Neurosci. 2021;15: 695479.PubMedPubMedCentralCrossRef
205.
Profaci CP, Munji RN, Pulido RS, Daneman R. The blood–brain barrier in health and disease: important unanswered questions. J Exp Med. 2020;217: e20190062.PubMedPubMedCentralCrossRef
206.
Takata F, Nakagawa S, Matsumoto J, Dohgu S. Blood-brain barrier dysfunction amplifies the development of neuroinflammation: understanding of cellular events in brain microvascular endothelial cells for prevention and treatment of BBB dysfunction. Front Cell Neurosci. 2021;15: 661838.PubMedPubMedCentralCrossRef
207.
Knopp RC, Banks WA, Erickson MA. Physical associations of microglia and the vascular blood-brain barrier and their importance in development, health, and disease. Curr Opin Neurobiol. 2022;77:102648.PubMedCrossRef
208.
Małkiewicz MA, Szarmach A, Sabisz A, Cubała WJ, Szurowska E, Winklewski PJ. Blood-brain barrier permeability and physical exercise. J Neuroinflammation. 2019;16:1.CrossRef
209.
Bertram S, Brixius K, Brinkmann C. Exercise for the diabetic brain: how physical training may help prevent dementia and Alzheimer’s disease in T2DM patients. Endocrine. 2016;53:350–63.PubMedCrossRef
210.
Soto I, Graham LC, Richter HJ, Simeone SN, Radell JE, Grabowska W, Funkhouser WK, Howell MC, Howell GR. APOE stabilization by exercise prevents aging neurovascular dysfunction and complement induction. PLoS Biol. 2015;13: e1002279.PubMedPubMedCentralCrossRef
211.
Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008;134:405–15.PubMedPubMedCentralCrossRef
212.
Liu H-W, Chang S-J. Moderate exercise suppresses NF-κB signaling and activates the SIRT1-AMPK-PGC1α axis to attenuate muscle loss in diabetic db/db mice. Front Physiol. 2018;9:636.PubMedPubMedCentralCrossRef
213.
Salminen A, Hyttinen JMT, Kaarniranta K. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. J Mol Med. 2011;89:667–76.PubMedCrossRef
214.
Shu HF, Yang T, Yu SX, Huang HD, Jiang LL, Gu JW, Kuang YQ. Aerobic exercise for Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 2014;9: e100503.ADSPubMedPubMedCentralCrossRef
215.
Dauwan M, Begemann MJ, Heringa SM, Sommer IE. Exercise improves clinical symptoms, quality of life, global functioning, and depression in Schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2016;42:588–99.PubMedCrossRef
216.
Fiuza-Luces C, Santos-Lozano A, Joyner M, Carrera-Bastos P, Picazo O, Zugaza JL, Izquierdo M, Ruilope LM, Lucia A. Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors. Nat Rev Cardiol. 2018;15:731–43.PubMedCrossRef
217.
Boa BCS, Yudkin JS, van Hinsbergh VWM, Bouskela E, Eringa EC. Exercise effects on perivascular adipose tissue: endocrine and paracrine determinants of vascular function. Br J Pharmacol. 2017;174:3466–81.PubMedPubMedCentralCrossRef
218.
Ruiz-Casado A, Martin-Ruiz A, Perez LM, Provencio M, Fiuza-Luces C, Lucia A. Exercise and the hallmarks of cancer. Trends Cancer. 2017;3:423–41.PubMedCrossRef
219.
Choi SH, Bylykbashi E, Chatila ZK, Lee SW, Pulli B, Clemenson GD, Kim E, Rompala A, Oram MK, Asselin C, et al. Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer’s mouse model. Science. 2018;361:eaan8821.PubMedPubMedCentralCrossRef
220.
Chen Y, Sun Y, Luo Z, Lin J, Qi B, Kang X, Ying C, Guo C, Yao M, Chen X, et al. Potential mechanism underlying exercise upregulated circulating blood exosome miR-215-5p to prevent necroptosis of neuronal cells and a model for early diagnosis of Alzheimer’s disease. Front Aging Neurosci. 2022;14: 860364.PubMedPubMedCentralCrossRef
221.
Knaepen K, Goekint M, Heyman EM, Meeusen R. Neuroplasticity-exercise-induced response of peripheral brain-derived neurotrophic factor: a systematic review of experimental studies in human subjects. Sports Med. 2010;40:765–801.PubMedCrossRef
222.
Koo JH, Kwon IS, Kang EB, Lee CK, Lee NH, Kwon MG, Cho IH, Cho JY. Neuroprotective effects of treadmill exercise on BDNF and PI3-K/Akt signaling pathway in the cortex of transgenic mice model of Alzheimer’s disease. J Exerc Nutrition Biochem. 2013;17:151–60.PubMedPubMedCentralCrossRef
223.
Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. In: Lewin GR, Carter BD, editors. Neurotrophic factors, handbook of experimental pharmacology. Berlin: Springer; 2014. p. 223–50.CrossRef
224.
Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev. 2008;59:201–20.PubMedCrossRef
225.
Kowiański P, Lietzau G, Czuba E, Waśkow M, Steliga A, Moryś J. BDNF: a key factor with multipotent impact on brain signaling and synaptic plasticity. Cell Mol Neurobiol. 2017;38:579–93.PubMedPubMedCentralCrossRef
226.
Gao L, Zhang Y, Sterling K, Song W. Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential. Transl Neurodegener. 2022;11:4.PubMedPubMedCentralCrossRef
227.
Ng TKS, Ho CSH, Tam WWS, Kua EH, Ho RC. Decreased serum brain-derived neurotrophic factor (BDNF) levels in patients with Alzheimer’s disease (AD): a systematic review and meta-analysis. Int J Mol Sci. 2019;20:257.PubMedPubMedCentralCrossRef
228.
Mori Y, Tsuji M, Oguchi T, Kasuga K, Kimura A, Futamura A, Sugimoto A, Kasai H, Kuroda T, Yano S, et al. Serum BDNF as a potential biomarker of Alzheimer’s disease: verification through assessment of serum, cerebrospinal fluid, and medial temporal lobe atrophy. Front Neurol. 2021;12: 653267.PubMedPubMedCentralCrossRef
229.
Angelucci F, Spalletta G, di Iulio F, Ciaramella A, Salani F, Colantoni L, Varsi AE, Gianni W, Sancesario G, Caltagirone C, Bossu P. Alzheimer’s disease (AD) and mild cognitive impairment (MCI) patients are characterized by increased BDNF serum levels. Curr Alzheimer Res. 2010;7:15–20.PubMedCrossRef
230.
McEwen LM, Gatev EG, Jones MJ, MacIsaac JL, McAllister MM, Goulding RE, Madden KM, Dawes MG, Kobor MS, Ashe MC. DNA methylation signatures in peripheral blood mononuclear cells from a lifestyle intervention for women at midlife: a pilot randomized controlled trial. Appl Physiol Nutr Metab. 2018;43:233–9.PubMedCrossRef
231.
Nagata T, Kobayashi N, Ishii J, Shinagawa S, Nakayama R, Shibata N, Kuerban B, Ohnuma T, Kondo K, Arai H, et al. Association between DNA methylation of the BDNF promoter region and clinical presentation in Alzheimer’s disease. Dement Geriatr Cogn Dis Extra. 2015;5:64–73.PubMedPubMedCentralCrossRef
232.
Lima Giacobbo B, Doorduin J, Klein HC, Dierckx RAJO, Bromberg E, de Vries EFJ. Brain-derived neurotrophic factor in brain disorders: focus on neuroinflammation. Mol Neurobiol. 2018;56:3295–312.PubMedPubMedCentralCrossRef
233.
Kopec BM, Zhao L, Rosa-Molinar E, Siahaan TJ. Non-invasive brain delivery and efficacy of BDNF in APP/PS1 transgenic mice as a model of Alzheimer’s disease. Med Res Arch. 2020;8:2043.PubMedPubMedCentralCrossRef
234.
Parrini M, Ghezzi D, Deidda G, Medrihan L, Castroflorio E, Alberti M, Baldelli P, Cancedda L, Contestabile A. Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome. Sci Rep. 2017;7:16825.ADSPubMedPubMedCentralCrossRef
235.
Gao L, Tian M, Zhao H-Y, Xu Q-Q, Huang Y-M, Si Q-C, Tian Q, Wu Q-M, Hu X-M, Sun L-B, et al. TrkB activation by 7, 8-dihydroxyflavone increases synapse AMPA subunits and ameliorates spatial memory deficits in a mouse model of Alzheimer’s disease. J Neurochem. 2016;136:620–36.PubMedCrossRef
236.
Carniel BP, da Rocha NS. Brain-derived neurotrophic factor (BDNF) and inflammatory markers: perspectives for the management of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2021;108: 110151.PubMedCrossRef
237.
Caviedes A, Lafourcade C, Soto C, Wyneken U. BDNF/NF-kappaB signaling in the neurobiology of depression. Curr Pharm Des. 2017;23:3154–63.PubMedCrossRef
238.
Caruso GI, Spampinato SF, Costantino G, Merlo S, Sortino MA. SIRT1-dependent upregulation of BDNF in human microglia challenged with Aβ: an early but transient response rescued by melatonin. Biomedicines. 2021;9:466.PubMedPubMedCentralCrossRef
239.
Ding H, Chen J, Su M, Lin Z, Zhan H, Yang F, Li W, Xie J, Huang Y, Liu X, et al. BDNF promotes activation of astrocytes and microglia contributing to neuroinflammation and mechanical allodynia in cyclophosphamide-induced cystitis. J Neuroinflammation. 2020;17:19.PubMedPubMedCentralCrossRef
240.
Poduslo JF, Curran GL. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res. 1996;36:280–6.PubMedCrossRef
241.
Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009;5:311–22.PubMedCrossRef
242.
Chapman CD, Frey WH 2nd, Craft S, Danielyan L, Hallschmid M, Schioth HB, Benedict C. Intranasal treatment of central nervous system dysfunction in humans. Pharm Res. 2013;30:2475–84.PubMedCrossRef
243.
Kandalam S, Sindji L, Delcroix GJ, Violet F, Garric X, Andre EM, Schiller PC, Venier-Julienne MC, de Rieux A, Guicheux J, Montero-Menei CN. Pharmacologically active microcarriers delivering BDNF within a hydrogel: Novel strategy for human bone marrow-derived stem cells neural/neuronal differentiation guidance and therapeutic secretome enhancement. Acta Biomater. 2017;49:167–80.PubMedCrossRef
244.
Demikhov VG. Outcomes and prognosis of diseases caused by Inkoo and Tahyna viruses. Vopr Virusol. 1995;40:72–4.PubMed
245.
246.
247.
Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Bostrom EA, Choi JH, Long JZ, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463–8.ADSPubMedPubMedCentralCrossRef
248.
Perakakis N, Triantafyllou GA, Fernandez-Real JM, Huh JY, Park KH, Seufert J, Mantzoros CS. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017;13:324–37.PubMedPubMedCentralCrossRef
249.
Wang Y, Tian M, Tan J, Pei X, Lu C, Xin Y, Deng S, Zhao F, Gao Y, Gong Y. Irisin ameliorates neuroinflammation and neuronal apoptosis through integrin alphaVbeta5/AMPK signaling pathway after intracerebral hemorrhage in mice. J Neuroinflammation. 2022;19:82.PubMedPubMedCentralCrossRef
250.
Briken S, Rosenkranz SC, Keminer O, Patra S, Ketels G, Heesen C, Hellweg R, Pless O, Schulz K-H, Gold SM. Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis. J Neuroimmunol. 2016;299:53–8.PubMedCrossRef
251.
Rabiee F, Lachinani L, Ghaedi S, Nasr-Esfahani MH, Megraw TL, Ghaedi K. New insights into the cellular activities of Fndc5/Irisin and its signaling pathways. Cell Biosci. 2020;10:51.PubMedPubMedCentralCrossRef
252.
de Oliveira M, De Sibio MT, Mathias LS, Rodrigues BM, Sakalem ME, Nogueira CR. Irisin modulates genes associated with severe coronavirus disease (COVID-19) outcome in human subcutaneous adipocytes cell culture. Mol Cell Endocrinol. 2020;515: 110917.PubMedPubMedCentralCrossRef
253.
Wang K, Song F, Xu K, Liu Z, Han S, Li F, Sun Y. Irisin attenuates neuroinflammation and prevents the memory and cognitive deterioration in Streptozotocin-induced diabetic mice. Mediators Inflamm. 2019;2019:1567179.PubMedPubMedCentralCrossRef
254.
Islam MR, Valaris S, Young MF, Haley EB, Luo R, Bond SF, Mazuera S, Kitchen RR, Caldarone BJ, Bettio LEB, et al. Exercise hormone irisin is a critical regulator of cognitive function. Nat Metab. 2021;3:1058–70.PubMedPubMedCentralCrossRef
255.
Lourenco MV, Ribeiro FC, Sudo FK, Drummond C, Assunção N, Vanderborght B, Tovar-Moll F, Mattos P, De Felice FG, Ferreira ST. Cerebrospinal fluid irisin correlates with amyloid-β, BDNF, and cognition in Alzheimer’s disease. Alzheimers Dement. 2020;12: e12034.
256.
Zhang F, Hou G, Hou G, Wang C, Shi B, Zheng Y. Serum irisin as a potential biomarker for cognitive decline in vascular dementia. Front Neurol. 2021;12:755046.PubMedPubMedCentralCrossRef
257.
Tsai C-L, Pai M-C. Circulating levels of Irisin in obese individuals at genetic risk for Alzheimer’s disease: correlations with amyloid-β, metabolic, and neurocognitive indices. Behav Brain Res. 2021;400: 113013.PubMedCrossRef
258.
259.
260.
Noda Y, Kuzuya A, Tanigawa K, Araki M, Kawai R, Ma B, Sasakura Y, Maesako M, Tashiro Y, Miyamoto M, et al. Fibronectin type III domain-containing protein 5 interacts with APP and decreases amyloid β production in Alzheimer’s disease. Mol Brain. 2018;11:1.CrossRef
261.
Peng J, Deng X, Huang W, Yu J-h, Wang J-x, Wang J-p, Yang S-b, Liu X, Wang L, Zhang Y, et al. Irisin protects against neuronal injury induced by oxygen-glucose deprivation in part depends on the inhibition of ROS-NLRP3 inflammatory signaling pathway. Mol Immunol. 2017;91:185–94.PubMedCrossRef
262.
Pignataro P, Dicarlo M, Zerlotin R, Zecca C, Dell’Abate MT, Buccoliero C, Logroscino G, Colucci S, Grano M. FNDC5/Irisin system in neuroinflammation and neurodegenerative diseases: update and novel perspective. Int J Mol Sci. 2021;22:1605.PubMedPubMedCentralCrossRef
263.
Hegazy MA, Abdelmonsif DA, Zeitoun TM, El-Sayed NS, Samy DM. Swimming exercise versus L-carnosine supplementation for Alzheimer’s dementia in rats: implication of circulating and hippocampal FNDC5/irisin. J Physiol Biochem. 2022;78:109–24.PubMedCrossRef
264.
Bretland KA, Lin L, Bretland KM, Smith MA, Fleming SM, Dengler-Crish CM. Irisin treatment lowers levels of phosphorylated tau in the hippocampus of pre-symptomatic female but not male htau mice. Neuropathol Appl Neurobiol. 2021;47:967–78.PubMedPubMedCentralCrossRef
265.
Welser-Alves JV, Boroujerdi A, Tigges U, Milner R. Microglia use multiple mechanisms to mediate interactions with vitronectin; non-essential roles for the highly-expressed alphavbeta3 and alphavbeta5 integrins. J Neuroinflammation. 2011;8:157.PubMedPubMedCentralCrossRef
266.
Lai S-W, Chen J-H, Lin H-Y, Liu Y-S, Tsai C-F, Chang P-C, Lu D-Y, Lin C. Regulatory effects of neuroinflammatory responses through brain-derived neurotrophic factor signaling in microglial cells. Mol Neurobiol. 2018;55:7487–99.PubMedCrossRef
267.
Chen F, Swartzlander DB, Ghosh A, Fryer JD, Wang B, Zheng H. Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology. Mol Neurodegener. 2021;16:5.PubMedPubMedCentralCrossRef
268.
Rodríguez-Rivera C, Garcia MM, Molina-Álvarez M, González-Martín C, Goicoechea C. Clusterin: always protecting. Synthesis, function and potential issues. Biomed Pharmacother. 2021;134:111174.PubMedCrossRef
269.
Moon HJ, Herring SK, Zhao L. Clusterin: a multifaceted protein in the brain. Neural Regen Res. 2021;16:1438–9.PubMedCrossRef
270.
Foster EM, Dangla-Valls A, Lovestone S, Ribe EM, Buckley NJ. Clusterin in Alzheimer’s disease: mechanisms, genetics, and lessons from other pathologies. Front Neurosci. 2019;13:164.PubMedPubMedCentralCrossRef
271.
Li X, Ma Y, Wei X, Li Y, Wu H, Zhuang J, Zhao Z. Clusterin in Alzheimer’s disease: a player in the biological behavior of amyloid-beta. Neurosci Bull. 2014;30:162–8.PubMedCrossRef
272.
Yu JT, Tan L. The role of clusterin in Alzheimer’s disease: pathways, pathogenesis, and therapy. Mol Neurobiol. 2012;45:314–26.PubMedCrossRef
273.
McGeer PL, Kawamata T, Walker DG. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 1992;579:337–41.PubMedCrossRef
274.
Lidstrom AM, Bogdanovic N, Hesse C, Volkman I, Davidsson P, Blennow K. Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer’s disease. Exp Neurol. 1998;154:511–21.PubMedCrossRef
275.
Nilselid AM, Davidsson P, Nagga K, Andreasen N, Fredman P, Blennow K. Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int. 2006;48:718–28.PubMedCrossRef
276.
Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Guntert A, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry. 2010;67:739–48.PubMedPubMedCentralCrossRef
277.
Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM. Plasma clusterin and the risk of Alzheimer disease. JAMA. 2011;305:1322–6.PubMedCrossRef
278.
Gupta VB, Doecke JD, Hone E, Pedrini S, Laws SM, Thambisetty M, Bush AI, Rowe CC, Villemagne VL, Ames D, et al. Plasma apolipoprotein J as a potential biomarker for Alzheimer’s disease: Australian imaging, biomarkers and lifestyle study of aging. Alzheimers Dement (Amst). 2016;3:18–26.PubMedCrossRef
279.
Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, Holtzman D, Morris JC, Bales K, Pickering EH, et al. A potential endophenotype for Alzheimer’s disease: cerebrospinal fluid clusterin. Neurobiol Aging. 2016;37(208):e201-208 e209.
280.
DeMattos RB, O’Dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, Paul SM, Aronow BJ, Holtzman DM. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA. 2002;99:10843–8.ADSPubMedPubMedCentralCrossRef
281.
Wojtas AM, Carlomagno Y, Sens JP, Kang SS, Jensen TD, Kurti A, Baker KE, Berry TJ, Phillips VR, Castanedes MC, et al. Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation. Acta Neuropathol Commun. 2020;8:210.PubMedPubMedCentralCrossRef
282.
Yuste-Checa P, Trinkaus VA, Riera-Tur I, Imamoglu R, Schaller TF, Wang H, Dudanova I, Hipp MS, Bracher A, Hartl FU. The extracellular chaperone clusterin enhances tau aggregate seeding in a cellular model. Nat Commun. 2021;12:4863.ADSPubMedPubMedCentralCrossRef
283.
De la Rosa A, Olaso-Gonzalez G, Arc-Chagnaud C, Millan F, Salvador-Pascual A, Garcia-Lucerga C, Blasco-Lafarga C, Garcia-Dominguez E, Carretero A, Correas AG, et al. Physical exercise in the prevention and treatment of Alzheimer’s disease. J Sport Health Sci. 2020;9:394–404.PubMedPubMedCentralCrossRef
284.
Wei JA, Liu L, Song X, Lin B, Cui J, Luo L, Liu Y, Li S, Li X, So KF, et al. Physical exercise modulates the microglial complement pathway in mice to relieve cortical circuitry deficits induced by mutant human TDP-43. Cell Rep. 2023;42: 112240.PubMedCrossRef
285.
Miguel ZD, Betley MJ, Willoughby D, Lehallier B, Olsson N, Bonanno L, Fairchild KJ, Contrepois K, Elias JE, Rando TA, Wyss-Coray T. Exercise conditioned plasma dampens inflammation via clusterin and boosts memory. bioRxiv. 2019. https://​doi.​org/​10.​1101/​775288.CrossRef
286.
Husain MA, Laurent B, Plourde M. APOE and Alzheimer’s disease: from lipid transport to physiopathology and therapeutics. Front Neurosci. 2021;15: 630502.PubMedPubMedCentralCrossRef
287.
Fernández-Calle R, Konings SC, Frontiñán-Rubio J, García-Revilla J, Camprubí-Ferrer L, Svensson M, Martinson I, Boza-Serrano A, Venero JL, Nielsen HM, et al. APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases. Mol Neurodegener. 2022;17:62.PubMedPubMedCentralCrossRef
288.
Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Wagner AC, Hama S, Hough G, Bachini E, Garber DW, Mishra VK, et al. An oral ApoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2005;25:1932–7.PubMedCrossRef
289.
Cordero-Llana O, Scott SA, Maslen SL, Anderson JM, Boyle J, Chowhdury RR, Tyers P, Barker RA, Kelly CM, Rosser AE, et al. Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cells. Cell Death Differ. 2011;18:907–13.PubMedPubMedCentralCrossRef
290.
Charnay Y, Imhof A, Vallet PG, Kovari E, Bouras C, Giannakopoulos P. Clusterin in neurological disorders: molecular perspectives and clinical relevance. Brain Res Bull. 2012;88:434–43.PubMedCrossRef
291.
Stephan JS, Sleiman SF. Exercise factors released by the liver, muscle, and bones have promising therapeutic potential for stroke. Front Neurol. 2021;12:600365.PubMedPubMedCentralCrossRef
292.
Townsend LK, MacPherson REK, Wright DC. New horizon: exercise and a focus on tissue-brain crosstalk. J Clin Endocrinol Metab. 2021;106:2147–63.PubMedCrossRef
293.
Maguire GA, Gossner A. Glycosyl phosphatidyl inositol phospholipase D activity in human serum. Ann Clin Biochem. 1995;32(Pt 1):74–8.PubMedCrossRef
294.
Metz CN, Schenkman S, Davitz MA. Characterization of the plasma glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD). Cell Biol Int Rep. 1991;15:875–82.PubMedCrossRef
295.
Rhode H, Lopatta E, Schulze M, Pascual C, Schulze HP, Schubert K, Schubert H, Reinhart K, Horn A. Glycosylphosphatidylinositol-specific phospholipase D in blood serum: is the liver the only source of the enzyme? Clin Chim Acta. 1999;281:127–45.PubMedCrossRef
296.
297.
Hoener MC, Stieger S, Brodbeck U. Isolation and characterization of a phosphatidylinositol-glycan-anchor-specific phospholipase D from bovine brain. Eur J Biochem. 1990;190:593–601.PubMedCrossRef
298.
Lierheimer R, Kunz B, Vogt L, Savoca R, Brodbeck U, Sonderegger P. The neuronal cell-adhesion molecule axonin-1 is specifically released by an endogenous glycosylphosphatidylinositol-specific phospholipase. Eur J Biochem. 1997;243:502–10.PubMedCrossRef
299.
Abdolmaleki F, Heidarianpour A. Endurance exercise training restores diabetes-induced alteration in circulating glycosylphosphatidylinositol-specific phospholipase D levels in rats. Diabetol Metab Syndr. 2020;12:1.CrossRef
300.
Brown HA, Thomas PG, Lindsley CW. Targeting phospholipase D in cancer, infection and neurodegenerative disorders. Nat Rev Drug Discov. 2017;16:351–67.PubMedPubMedCentralCrossRef
301.
Mato J, Alvarez L, Ortiz P, Pajares MA. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther. 1997;73:265–80.PubMedCrossRef
302.
303.
304.
Altuna M, Urdanoz-Casado A, Sanchez-Ruiz de Gordoa J, Zelaya MV, Labarga A, Lepesant JMJ, Roldan M, Blanco-Luquin I, Perdones A, Larumbe R, et al. DNA methylation signature of human hippocampus in Alzheimer’s disease is linked to neurogenesis. Clin Epigenetics. 2019;11:91.PubMedPubMedCentralCrossRef
305.
Pellegrini C, Pirazzini C, Sala C, Sambati L, Yusipov I, Kalyakulina A, Ravaioli F, Kwiatkowska KM, Durso DF, Ivanchenko M, et al. A meta-analysis of brain DNA methylation across sex, age, and Alzheimer’s disease points for accelerated epigenetic aging in neurodegeneration. Front Aging Neurosci. 2021;13: 639428.PubMedPubMedCentralCrossRef
306.
307.
Swiatowy WJ, Drzewiecka H, Kliber M, Sasiadek M, Karpinski P, Plawski A, Jagodzinski PP. Physical activity and DNA methylation in humans. Int J Mol Sci. 2021;22:12989.PubMedPubMedCentralCrossRef
308.
Ngwa JS, Nwulia E, Ntekim O, Bedada FB, Kwabi-Addo B, Nadarajah S, Johnson S, Southerland WM, Kwagyan J, Obisesan TO. Aerobic exercise training-induced changes on DNA methylation in mild cognitively impaired elderly african americans: gene, exercise, and memory study—GEMS-I. Front Mol Neurosci. 2022;14:752403.PubMedPubMedCentralCrossRef
309.
Xu M, Zhu J, Liu X-D, Luo M-Y, Xu N-J. Roles of physical exercise in neurodegeneration: reversal of epigenetic clock. Transl Neurodegener. 2021;10:1.CrossRef
310.
Wu C, Yang L, Tucker D, Dong Y, Zhu L, Duan R, Liu TC, Zhang Q. Beneficial effects of exercise pretreatment in a sporadic Alzheimer’s rat model. Med Sci Sports Exerc. 2018;50:945–56.PubMedPubMedCentralCrossRef
311.
Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol. 2012;57:1097–109.PubMedCrossRef
312.
Finkelstein JD. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine. Clin Chem Lab Med. 2007;45:1694–9.PubMedCrossRef
313.
314.
Lee S, Lemere CA, Frost JL, Shea TB. Dietary supplementation with S-adenosyl methionine delayed amyloid-β and tau pathology in 3xTg-AD mice. J Alzheimers Dis. 2012;28:423–31.PubMedCrossRef
315.
Fuso A, Seminara L, Cavallaro RA, D’Anselmi F, Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci. 2005;28:195–204.PubMedCrossRef
316.
Coppede F. Epigenetic regulation in Alzheimer’s disease: is it a potential therapeutic target? Expert Opin Ther Targets. 2021;25:283–98.PubMedCrossRef
317.
Chan A, Tchantchou F, Graves V, Rozen R, Shea TB. Dietary and genetic compromise in folate availability reduces acetylcholine, cognitive performance and increases aggression: critical role of S-adenosyl methionine. J Nutr Health Aging. 2008;12:252–61.PubMedCrossRef
318.
Fuso A, Nicolia V, Ricceri L, Cavallaro RA, Isopi E, Mangia F, Fiorenza MT, Scarpa S. S-adenosylmethionine reduces the progress of the Alzheimer-like features induced by B-vitamin deficiency in mice. Neurobiol Aging. 2012;33:1482.e1481-1482.e1416.CrossRef
319.
Tchantchou F, Graves M, Ortiz D, Chan A, Rogers E, Shea TB. S-adenosyl methionine: a connection between nutritional and genetic risk factors for neurodegeneration in Alzheimer’s disease. J Nutr Health Aging. 2006;10:541–4.PubMed
320.
Tchantchou F, Graves M, Falcone D, Shea TB. S-adenosylmethionine mediates glutathione efficacy by increasing glutathione S-transferase activity: implications for S-adenosyl methionine as a neuroprotective dietary supplement. J Alzheimers Dis. 2008;14:323–8.PubMedCrossRef
321.
Zhang Y, Ma R, Deng Q, Wang W, Cao C, Yu C, Li S, Shi L, Tian J. S-adenosylmethionine improves cognitive impairment in D-galactose-induced brain aging by inhibiting oxidative stress and neuroinflammation. J Chem Neuroanat. 2023;128:102232.PubMedCrossRef
322.
Li Q, Cui J, Fang C, Liu M, Min G, Li L, Gong C. S-Adenosylmethionine attenuates oxidative stress and neuroinflammation induced by amyloid-β through modulation of glutathione metabolism. J Alzheimers Dis. 2017;58:549–58.PubMedCrossRef
323.
Wang W, Zhao F, Ma X, Perry G, Zhu X. Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances. Mol Neurodegener. 2020;15:1.CrossRef
324.
Lam AB, Kervin K, Tanis JE. Vitamin B12 impacts amyloid beta-induced proteotoxicity by regulating the methionine/S-adenosylmethionine cycle. Cell Rep. 2021;36:109753.PubMedPubMedCentralCrossRef
325.
326.
Duarte FV, Palmeira CM, Rolo AP. The emerging role of mitomirs in the pathophysiology of human disease. In: Santulli G, editor. microRNA: medical evidence: advances in experimental medicine and biology. Cham: Springer; 2015. p. 123–54.CrossRef
327.
328.
329.
Nejad C, Stunden HJ, Gantier MP. A guide to miRNAs in inflammation and innate immune responses. FEBS J. 2018;285:3695–716.PubMedCrossRef
330.
Tili E, Michaille J-J, Costinean S, Croce CM. MicroRNAs, the immune system and rheumatic disease. Nat Clin Pract Rheumatol. 2008;4:534–41.PubMedCrossRef
331.
332.
Delay C, Mandemakers W, Hébert SS. MicroRNAs in Alzheimer’s disease. Neurobiol Dis. 2012;46:285–90.PubMedCrossRef
333.
Jaber VR, Zhao Y, Sharfman NM, Li W, Lukiw WJ. Addressing Alzheimer’s disease (AD) neuropathology using anti-microRNA (AM) strategies. Mol Neurobiol. 2019;56:8101–8.PubMedPubMedCentralCrossRef
334.
Silva FCd, Iop RdR, Andrade A, Costa VP, Gutierres Filho PJB, Silva RD. Effects of physical exercise on the expression of microRNAs: a systematic review. J Strength Cond Res. 2020;34:270–80.PubMedCrossRef
335.
Silva GJJ, Bye A, el Azzouzi H, Wisløff U. MicroRNAs as important regulators of exercise adaptation. Prog Cardiovasc Dis. 2017;60:130–51.PubMedCrossRef
336.
Xu T, Liu Q, Yao J, Dai Y, Wang H, Xiao J. Circulating microRNAs in response to exercise. Scand J Med Sci Sports. 2015;25:e149–54.PubMedCrossRef
337.
Osman A. MicroRNAs in health and disease—basic science and clinical applications. Clin Lab. 2012;58:393–402.PubMed
338.
339.
Liang Y, Wang L. Inflamma-microRNAs in Alzheimer’s disease: from disease pathogenesis to therapeutic potentials. Front Cell Neurosci. 2021;15: 785433.PubMedPubMedCentralCrossRef
340.
Walgrave H, Zhou L, De Strooper B, Salta E. The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives. Mol Neurodegener. 2021;16:76.PubMedPubMedCentralCrossRef
341.
342.
Walgrave H, Balusu S, Snoeck S, Vanden Eynden E, Craessaerts K, Thrupp N, Wolfs L, Horre K, Fourne Y, Ronisz A, et al. Restoring miR-132 expression rescues adult hippocampal neurogenesis and memory deficits in Alzheimer’s disease. Cell Stem Cell. 2021;28(1805–1821): e1808.
343.
Hansen KF, Karelina K, Sakamoto K, Wayman GA, Impey S, Obrietan K. miRNA-132: a dynamic regulator of cognitive capacity. Brain Struct Funct. 2013;218:817–31.PubMedCrossRef
344.
Salta E, Sierksma A, Vanden Eynden E, De Strooper B. miR-132 loss de-represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer’s brain. EMBO Mol Med. 2016;8:1005–18.PubMedPubMedCentralCrossRef
345.
Juzwik CA, Drake SS, Zhang Y, Paradis-Isler N, Sylvester A, Amar-Zifkin A, Douglas C, Morquette B, Moore CS, Fournier AE. microRNA dysregulation in neurodegenerative diseases: a systematic review. Prog Neurobiol. 2019;182:101664.PubMedCrossRef
346.
Fan W, Liang C, Ou M, Zou T, Sun F, Zhou H, Cui L. MicroRNA-146a is a wide-reaching neuroinflammatory regulator and potential treatment target in neurological diseases. Front Mol Neurosci. 2020;13:90.PubMedPubMedCentralCrossRef
347.
Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006;103:12481–6.ADSPubMedPubMedCentralCrossRef
348.
Martin NA, Hyrlov KH, Elkjaer ML, Thygesen EK, Wlodarczyk A, Elbaek KJ, Aboo C, Okarmus J, Benedikz E, Reynolds R, et al. Absence of miRNA-146a differentially alters microglia function and proteome. Front Immunol. 2020;11:1110.PubMedPubMedCentralCrossRef
349.
Soplinska A, Zareba L, Wicik Z, Eyileten C, Jakubik D, Siller-Matula JM, De Rosa S, Malek LA, Postula M. MicroRNAs as biomarkers of systemic changes in response to endurance exercise—a comprehensive review. Diagnostics. 2020;10:813.PubMedPubMedCentralCrossRef
350.
Alipour MR, Yousefzade N, Bavil FM, Naderi R, Ghiasi R. Swimming impacts on pancreatic inflammatory cytokines, miR-146a and NF-кB expression levels in type-2 diabetic rats. Curr Diabetes Rev. 2020;16:889–94.PubMedCrossRef
351.
Mai H, Fan W, Wang Y, Cai Y, Li X, Chen F, Chen X, Yang J, Tang P, Chen H, et al. Intranasal administration of miR-146a agomir rescued the pathological process and cognitive impairment in an AD mouse model. Mol Ther Nucleic Acids. 2019;18:681–95.PubMedPubMedCentralCrossRef
352.
Guedes JR, Santana I, Cunha C, Duro D, Almeida MR, Cardoso AM, de Lima MC, Cardoso AL. MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer’s disease. Alzheimers Dement (Amst). 2016;3:7–17.PubMedCrossRef
353.
Lukiw WJ, Alexandrov PN, Zhao Y, Hill JM, Bhattacharjee S. Spreading of Alzheimer’s disease inflammatory signaling through soluble micro-RNA. NeuroReport. 2012;23:621–6.PubMedPubMedCentral
354.
Guedes JR, Custodia CM, Silva RJ, de Almeida LP, de Pedroso Lima MC, Cardoso AL. Early miR-155 upregulation contributes to neuroinflammation in Alzheimer’s disease triple transgenic mouse model. Hum Mol Genet. 2014;23:6286–301.PubMedCrossRef
355.
Teter B, Morihara T, Lim GP, Chu T, Jones MR, Zuo X, Paul RM, Frautschy SA, Cole GM. Curcumin restores innate immune Alzheimer’s disease risk gene expression to ameliorate Alzheimer pathogenesis. Neurobiol Dis. 2019;127:432–48.PubMedPubMedCentralCrossRef
356.
Liu D, Zhao D, Zhao Y, Wang Y, Zhao Y, Wen C. Inhibition of microRNA-155 alleviates cognitive impairment in Alzheimer’s disease and involvement of neuroinflammation. Curr Alzheimer Res. 2019;16:473–82.PubMedCrossRef
357.
Zhao J, Zhou Y, Guo M, Yue D, Chen C, Liang G, Xu L. MicroRNA-7: expression and function in brain physiological and pathological processes. Cell Biosci. 2020;10:1.CrossRef
358.
Feng M-G, Liu C-F, Chen L, Feng W-B, Liu M, Hai H, Lu J-M. MiR-21 attenuates apoptosis-triggered by amyloid-β via modulating PDCD4/ PI3K/AKT/GSK-3β pathway in SH-SY5Y cells. Biomed Pharmacother. 2018;101:1003–7.PubMedCrossRef
359.
Long JM, Ray B, Lahiri DK. MicroRNA-339-5p Down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. J Biol Chem. 2014;289:5184–98.PubMedCrossRef
360.
361.
Jorgensen SB, Richter EA, Wojtaszewski JF. Role of AMPK in skeletal muscle metabolic regulation and adaptation in relation to exercise. J Physiol. 2006;574:17–31.PubMedPubMedCentralCrossRef
362.
363.
Wang J, Gallagher D, DeVito LM, Cancino GI, Tsui D, He L, Keller GM, Frankland PW, Kaplan DR, Miller FD. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell. 2012;11:23–35.PubMedCrossRef
364.
van Niekerk G, Mabin T, Engelbrecht AM. Anti-inflammatory mechanisms of cannabinoids: an immunometabolic perspective. Inflammopharmacology. 2019;27:39–46.PubMedCrossRef
365.
Chen X, Li X, Zhang W, He J, Xu B, Lei B, Wang Z, Cates C, Rousselle T, Li J. Activation of AMPK inhibits inflammatory response during hypoxia and reoxygenation through modulating JNK-mediated NF-kappaB pathway. Metabolism. 2018;83:256–70.PubMedPubMedCentralCrossRef
366.
367.
Kauppinen A, Suuronen T, Ojala J, Kaarniranta K, Salminen A. Antagonistic crosstalk between NF-kappaB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal. 2013;25:1939–48.PubMedCrossRef
368.
Yang H, Zhang W, Pan H, Feldser HG, Lainez E, Miller C, Leung S, Zhong Z, Zhao H, Sweitzer S, et al. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-kappaB activity. PLoS ONE. 2012;7: e46364.ADSPubMedPubMedCentralCrossRef
369.
Youssef ME, Abd El-Fattah EE, Abdelhamid AM, Eissa H, El-Ahwany E, Amin NA, Hetta HF, Mahmoud MH, Batiha GE, Gobba N, et al. Interference with the AMPKalpha/mTOR/NLRP3 signaling and the IL-23/IL-17 axis effectively protects against the dextran sulfate sodium intoxication in rats: a new paradigm in empagliflozin and metformin reprofiling for the management of ulcerative colitis. Front Pharmacol. 2021;12: 719984.PubMedPubMedCentralCrossRef
370.
Chen MY, Ye XJ, He XH, Ouyang DY. The signaling pathways regulating NLRP3 inflammasome activation. Inflammation. 2021;44:1229–45.PubMedCrossRef
371.
372.
Wang Z, van Praag H. Exercise and the brain: neurogenesis, synaptic plasticity, spine density, and angiogenesis. In: Boecker H, Hillman CH, Scheef L, Strüder HK, editors. Functional neuroimaging in exercise and sport sciences. New York: Springer; 2012. p. 3–24.CrossRef
373.
Spielman LJ, Little JP, Klegeris A. Physical activity and exercise attenuate neuroinflammation in neurological diseases. Brain Res Bull. 2016;125:19–29.PubMedCrossRef
374.
Lin JY, Kuo WW, Baskaran R, Kuo CH, Chen YA, Chen WS, Ho TJ, Day CH, Mahalakshmi B, Huang CY. Swimming exercise stimulates IGF1/ PI3K/Akt and AMPK/SIRT1/PGC1alpha survival signaling to suppress apoptosis and inflammation in aging hippocampus. Aging (Albany NY). 2020;12:6852–64.PubMedCrossRef
375.
Azimi M, Gharakhanlou R, Naghdi N, Khodadadi D, Heysieattalab S. Moderate treadmill exercise ameliorates amyloid-β-induced learning and memory impairment, possibly via increasing AMPK activity and up-regulation of the PGC-1α/FNDC5/BDNF pathway. Peptides. 2018;102:78–88.PubMedCrossRef
376.
Morais GP, de Sousa Neto IV, Marafon BB, Ropelle ER, Cintra DE, Pauli JR, Silva A. The dual and emerging role of physical exercise-induced TFEB activation in the protection against Alzheimer’s disease. J Cell Physiol. 2023;238:954–65.PubMedCrossRef
377.
Tao L, Pashley DH. The relationship between dentin bond strengths and dentin permeability. Dent Mater. 1989;5:133–9.PubMedCrossRef
378.
379.
Palasz E, Niewiadomski W, Gasiorowska A, Wysocka A, Stepniewska A, Niewiadomska G. Exercise-induced neuroprotection and recovery of motor function in animal models of Parkinson’s disease. Front Neurol. 2019;10:1143.PubMedPubMedCentralCrossRef
380.
Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem. 1995;229:558–65.PubMedCrossRef
381.
Sanchez J, Nozhenko Y, Palou A, Rodriguez AM. Free fatty acid effects on myokine production in combination with exercise mimetics. Mol Nutr Food Res. 2013;57:1456–67.PubMedCrossRef
382.
Lauritzen HP, Brandauer J, Schjerling P, Koh HJ, Treebak JT, Hirshman MF, Galbo H, Goodyear LJ. Contraction and AICAR stimulate IL-6 vesicle depletion from skeletal muscle fibers in vivo. Diabetes. 2013;62:3081–92.PubMedPubMedCentralCrossRef
383.
Xiang H-C, Lin L-X, Hu X-F, Zhu H, Li H-P, Zhang R-Y, Hu L, Liu W-T, Zhao Y-L, Shu Y, et al. AMPK activation attenuates inflammatory pain through inhibiting NF-κB activation and IL-1β expression. J Neuroinflammation. 2019;16:1.CrossRef
384.
Ayasolla KR, Giri S, Singh AK, Singh I. 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) attenuates the expression of LPS- and Aβ peptide-induced inflammatory mediators in astroglia. J Neuroinflammation. 2005;2:21.PubMedPubMedCentralCrossRef
385.
He G, Zhang YW, Lee JH, Zeng SX, Wang YV, Luo Z, Dong XC, Viollet B, Wahl GM, Lu H. AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity. Mol Cell Biol. 2014;34:148–57.PubMedPubMedCentralCrossRef
386.
Li H, Wu J, Zhu L, Sha L, Yang S, Wei J, Ji L, Tang X, Mao K, Cao L, et al. Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer’s disease: possible mechanisms of IDE in T2D and AD. Biosci Rep. 2018;38:BSR20170862.PubMedPubMedCentralCrossRef
387.
Du L-L, Chai D-M, Zhao L-N, Li X-H, Zhang F-C, Zhang H-B, Liu L-B, Wu K, Liu R, Wang J-Z, Zhou X-W. AMPK activation ameliorates Alzheimer’s disease-like pathology and spatial memory impairment in a streptozotocin-induced Alzheimer’s disease model in rats. J Alzheimers Dis. 2014;43:775–84.CrossRef
388.
389.
Kobilo T, Guerrieri D, Zhang Y, Collica SC, Becker KG, van Praag H. AMPK agonist AICAR improves cognition and motor coordination in young and aged mice. Learn Mem. 2014;21:119–26.PubMedPubMedCentralCrossRef
390.
Lv Z, Guo Y. Metformin and its benefits for various diseases. Front Endocrinol. 2020;11:191.CrossRef
391.
Vial G, Detaille D, Guigas B. Role of mitochondria in the mechanism(s) of action of metformin. Front Endocrinol. 2019;10:294.CrossRef
392.
Viollet B, Guigas B, Garcia NS, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci. 2011;122:253–70.CrossRef
393.
Khezri MR, Yousefi K, Mahboubi N, Hodaei D, Ghasemnejad-Berenji M. Metformin in Alzheimer’s disease: an overview of potential mechanisms, preclinical and clinical findings. Biochem Pharmacol. 2022;197:114945.PubMedCrossRef
394.
Sanati M, Aminyavari S, Afshari AR, Sahebkar A. Mechanistic insight into the role of metformin in Alzheimer’s disease. Life Sci. 2022;291:120299.PubMedCrossRef
395.
Cheng JT, Huang CC, Liu IM, Tzeng TF, Chang CJ. Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats. Diabetes. 2006;55:819–25.PubMedCrossRef
396.
Matsui Y, Hirasawa Y, Sugiura T, Toyoshi T, Kyuki K, Ito M. Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice. Biol Pharm Bull. 2010;33:963–70.PubMedCrossRef
397.
Kim SA, Choi HC. Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells. Biochem Biophys Res Commun. 2012;425:866–72.PubMedCrossRef
398.
Kelly B, Tannahill GM, Murphy MP, O’Neill LA. Metformin inhibits the production of reactive oxygen species from NADH: ubiquinone oxidoreductase to limit induction of interleukin-1beta (IL-1beta) and boosts interleukin-10 (IL-10) in lipopolysaccharide (LPS)-activated macrophages. J Biol Chem. 2015;290:20348–59.PubMedPubMedCentralCrossRef
399.
Gu J, Ye S, Wang S, Sun W, Hu Y. Metformin inhibits nuclear factor-kappaB activation and inflammatory cytokines expression induced by high glucose via adenosine monophosphate-activated protein kinase activation in rat glomerular mesangial cells in vitro. Chin Med J (Engl). 2014;127:1755–60.PubMedCrossRef
400.
Andrews M, Soto N, Arredondo M. Effect of metformin on the expression of tumor necrosis factor-alpha, Toll like receptors 2/4 and C reactive protein in obese type-2 diabetic patients. Rev Med Chil. 2012;140:1377–82.PubMedCrossRef
401.
Xu X, Du C, Zheng Q, Peng L, Sun Y. Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review. BMC Womens Health. 2014;14:93.PubMedPubMedCentralCrossRef
402.
Campbell JM, Stephenson MD, de Courten B, Chapman I, Bellman SM, Aromataris E. Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and meta-analysis. J Alzheimers Dis. 2018;65:1225–36.PubMedPubMedCentralCrossRef
403.
Sluggett JK, Koponen M, Bell JS, Taipale H, Tanskanen A, Tiihonen J, Uusitupa M, Tolppanen AM, Hartikainen S. Metformin and risk of Alzheimer’s disease among community-dwelling people with diabetes: a national case-control study. J Clin Endocrinol Metab. 2020;105: e963.CrossRef
404.
Hsu CC, Wahlqvist ML, Lee MS, Tsai HN. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis. 2011;24:485–93.PubMedCrossRef
405.
Luchsinger JA, Perez T, Chang H, Mehta P, Steffener J, Pradabhan G, Ichise M, Manly J, Devanand DP, Bagiella E. Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial. J Alzheimers Dis. 2016;51:501–14.PubMedPubMedCentralCrossRef
406.
Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based case-control study. J Am Geriatr Soc. 2012;60:916–21.PubMedCrossRef
407.
Ha J, Choi DW, Kim KJ, Cho SY, Kim H, Kim KY, Koh Y, Nam CM, Kim E. Association of metformin use with Alzheimer’s disease in patients with newly diagnosed type 2 diabetes: a population-based nested case-control study. Sci Rep. 2021;11:24069.ADSPubMedPubMedCentralCrossRef
408.
Tabatabaei Malazy O, Bandarian F, Qorbani M, Mohseni S, Mirsadeghi S, Peimani M, Larijani B. The effect of metformin on cognitive function: a systematic review and meta-analysis. J Psychopharmacol. 2022;36:666–79.PubMedCrossRef
409.
Bell DS. Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. South Med J. 2010;103:265–7.PubMedCrossRef
410.
Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B. Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis. 2014;41:61–8.PubMedCrossRef
411.
Mu L, Xia D, Cai J, Gu B, Liu X, Friedman V, Liu QS, Zhao L. Treadmill exercise reduces neuroinflammation, glial cell activation and improves synaptic transmission in the prefrontal cortex in 3 x Tg-AD mice. Int J Mol Sci. 2022;23:12655.PubMedPubMedCentralCrossRef
412.
Lu Y, Dong Y, Tucker D, Wang R, Ahmed ME, Brann D, Zhang Q. Treadmill exercise exerts neuroprotection and regulates microglial polarization and oxidative stress in a streptozotocin-induced rat model of sporadic Alzheimer’s disease. J Alzheimers Dis. 2017;56:1469–84.PubMedPubMedCentralCrossRef
413.
Leem YH, Lee YI, Son HJ, Lee SH. Chronic exercise ameliorates the neuroinflammation in mice carrying NSE/htau23. Biochem Biophys Res Commun. 2011;406:359–65.PubMedCrossRef
414.
Kohman RA, Bhattacharya TK, Wojcik E, Rhodes JS. Exercise reduces activation of microglia isolated from hippocampus and brain of aged mice. J Neuroinflammation. 2013;10:114.PubMedPubMedCentralCrossRef
415.
Nichol KE, Poon WW, Parachikova AI, Cribbs DH, Glabe CG, Cotman CW. Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation. 2008;5:13.PubMedPubMedCentralCrossRef
416.
Svensson M, Andersson E, Manouchehrian O, Yang Y, Deierborg T. Voluntary running does not reduce neuroinflammation or improve non-cognitive behavior in the 5xFAD mouse model of Alzheimer’s disease. Sci Rep. 2020;10:1346.ADSPubMedPubMedCentralCrossRef
417.
Medhat E, Rashed L, Abdelgwad M, Aboulhoda BE, Khalifa MM, El-Din SS. Exercise enhances the effectiveness of vitamin D therapy in rats with Alzheimer’s disease: emphasis on oxidative stress and inflammation. Metab Brain Dis. 2020;35:111–20.PubMedCrossRef
418.
Liu Y, Chu JMT, Yan T, Zhang Y, Chen Y, Chang RCC, Wong GTC. Short-term resistance exercise inhibits neuroinflammation and attenuates neuropathological changes in 3xTg Alzheimer’s disease mice. J Neuroinflammation. 2020;17:4.PubMedPubMedCentralCrossRef
419.
Hashiguchi D, Campos HC, Wuo-Silva R, Faber J, da Gomes S, Coppi AA, Arida RM, Longo BM. Resistance exercise decreases amyloid load and modulates inflammatory responses in the APP/PS1 mouse model for Alzheimer’s disease. J Alzheimers Dis. 2020;73:1525–39.PubMedCrossRef
420.
de Farias JM, Dos Santos TN, Pereira EV, de Moraes GL, Furtado BG, Tietbohl LTW, Da Costa PB, Simon KU, Muller AP. Physical exercise training improves judgment and problem-solving and modulates serum biomarkers in patients with Alzheimer’s disease. Mol Neurobiol. 2021;58:4217–25.PubMedCrossRef
421.
Abd El-Kader SM, Al-Jiffri OH. Aerobic exercise improves quality of life, psychological well-being and systemic inflammation in subjects with Alzheimer’s disease. Afr Health Sci. 2016;16:1045–55.PubMedPubMedCentralCrossRef
422.
Tsai CL, Pai MC, Ukropec J, Ukropcova B. Distinctive effects of aerobic and resistance exercise modes on neurocognitive and biochemical changes in individuals with mild cognitive impairment. Curr Alzheimer Res. 2019;16:316–32.PubMedCrossRef
Metadata
Title
Exercise mimetics: a novel strategy to combat neuroinflammation and Alzheimer’s disease
Author
Renqing Zhao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2024
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-024-03031-9

Other articles of this Issue 1/2024

Journal of Neuroinflammation 1/2024 Go to the issue

Research

CD4 T-cell aging exacerbates neuroinflammation in a late-onset mouse model of amyotrophic lateral sclerosis

Research

Increased regulatory activity of intestinal innate lymphoid cells type 3 (ILC3) prevents experimental autoimmune encephalomyelitis severity

Research

Peritoneal sepsis caused by Escherichia coli triggers brainstem inflammation and alters the function of sympatho-respiratory control circuits

Research

Protecting effects of 4-octyl itaconate on neonatal hypoxic-ischemic encephalopathy via Nrf2 pathway in astrocytes

Research

Monocytes release cystatin F dimer to associate with Aβ and aggravate amyloid pathology and cognitive deficits in Alzheimer’s disease

Research

Gut microbiota, circulating cytokines and dementia: a Mendelian randomization study